• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例肾细胞癌血管内皮生长因子抑制剂治疗患者的脾动脉瘤破裂。

A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.

机构信息

Northern Ontario School of Medicine, Lakehead University, Thunder Bay, Ontario, P3E 2C6, Canada.

Diagnostic Imaging Department, Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, P7B 6V4, Canada.

出版信息

Cancer Rep (Hoboken). 2022 Aug;5(8):e1567. doi: 10.1002/cnr2.1567. Epub 2021 Oct 28.

DOI:10.1002/cnr2.1567
PMID:34713631
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9351660/
Abstract

BACKGROUND

Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing awareness of the association of arterial aneurysms and dissections with vascular endothelial growth factor inhibitor use, although, few reports exist for pazopanib.

CASE

Here we report a 69-year-old patient with minimal cardiovascular risk factors who developed a rupture of a splenic arterial aneurysm after more than 5 years of effective treatment with pazopanib for metastatic renal cell carcinoma.

CONCLUSION

This case report outlines the necessity to monitor patients while on pazopanib, even when there are minimal risk factors and long periods of tolerance.

摘要

背景

帕唑帕尼是一种血管内皮生长因子抑制剂，用于治疗转移性肾细胞癌。上市后报告表明，人们越来越意识到血管内皮生长因子抑制剂的使用与动脉动脉瘤和夹层的关联，尽管针对帕唑帕尼的报告很少。

病例

在这里，我们报告了一例 69 岁的患者，该患者患有最小的心血管危险因素，在转移性肾细胞癌用帕唑帕尼有效治疗超过 5 年后，发生了脾动脉动脉瘤破裂。

结论

本病例报告概述了在使用帕唑帕尼时监测患者的必要性，即使存在最小的危险因素和长时间的耐受。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/af1c0b6a2b93/CNR2-5-e1567-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/bd41cc935b69/CNR2-5-e1567-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/65fc433c4929/CNR2-5-e1567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/af1c0b6a2b93/CNR2-5-e1567-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/bd41cc935b69/CNR2-5-e1567-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/65fc433c4929/CNR2-5-e1567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25df/9351660/af1c0b6a2b93/CNR2-5-e1567-g003.jpg

相似文献

1
A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.一例肾细胞癌血管内皮生长因子抑制剂治疗患者的脾动脉瘤破裂。
Cancer Rep (Hoboken). 2022 Aug;5(8):e1567. doi: 10.1002/cnr2.1567. Epub 2021 Oct 28.
2
Co-administration of pazopanib and enteral nutrition with omega-3 fatty acids as a safety issue in a patient treated for metastatic clear cell renal cancer: A case report.帕唑帕尼与欧米伽-3 脂肪酸联合肠内营养作为转移性透明细胞肾细胞癌治疗患者的安全性问题：一例报告。
J Cancer Res Ther. 2023 Jan-Mar;19(2):474-476. doi: 10.4103/jcrt.jcrt_533_22.
3
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.一线使用帕唑帕尼治疗，随后使用血管内皮生长因子受体酪氨酸激酶抑制剂或雷帕霉素靶蛋白抑制剂治疗的未经选择的转移性透明细胞肾细胞癌患者的结局：单机构经验
BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13.
4
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.帕唑帕尼致肾细胞癌患者可逆性后部脑病综合征
J Clin Pharm Ther. 2013 Apr;38(2):175-6. doi: 10.1111/jcpt.12031. Epub 2012 Dec 4.
5
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.一项意大利、多中心、真实世界、回顾性研究，评估一线帕唑帕尼治疗未经选择的转移性肾细胞癌患者：'Pamerit'研究。
Jpn J Clin Oncol. 2021 Mar 3;51(3):484-491. doi: 10.1093/jjco/hyaa193.
6
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.帕唑帕尼联合贝伐珠单抗治疗转移性肾细胞癌或其他晚期肿瘤患者的 I 期剂量递增研究。
BMC Cancer. 2017 Aug 15;17(1):547. doi: 10.1186/s12885-017-3527-7.
7
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.帕唑帕尼与舒尼替尼治疗具有高风险特征的转移性肾细胞癌患者的疗效比较
Cancer Chemother Pharmacol. 2016 Aug;78(2):325-32. doi: 10.1007/s00280-016-3093-8. Epub 2016 Jun 21.
8
Pazopanib for the treatment of metastatic renal cell carcinoma.帕唑帕尼治疗转移性肾细胞癌。
Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16.
9
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.帕唑帕尼及其他抗血管内皮生长因子治疗肾细胞癌时肝毒性的发生情况：一项利用分布式数据库网络的观察性研究
Cancer Chemother Pharmacol. 2016 Sep;78(3):559-66. doi: 10.1007/s00280-016-3112-9. Epub 2016 Jul 20.
10
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.帕唑帕尼相关性肿瘤溶解综合征伴转移性透明细胞肾细胞癌：一例报告。
Invest New Drugs. 2018 Jun;36(3):513-516. doi: 10.1007/s10637-018-0576-y. Epub 2018 Feb 20.

引用本文的文献

1
Endovascular and Open Surgical Treatment of Ruptured Splenic Artery Aneurysms: A Case Report and a Systematic Literature Review.破裂性脾动脉瘤的血管内治疗与开放手术治疗：一例报告及系统文献综述
J Clin Med. 2023 Sep 20;12(18):6085. doi: 10.3390/jcm12186085.

本文引用的文献

1
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.系统性血管内皮生长因子抑制剂相关的动脉瘤和夹层：FDA 不良事件报告系统报告病例及文献报道的综述。
Vasc Med. 2021 Oct;26(5):526-534. doi: 10.1177/1358863X211006470. Epub 2021 Apr 12.
2
The Impact of Pazopanib on the Cardiovascular System.帕唑帕尼对心血管系统的影响。
J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):387-398. doi: 10.1177/1074248418769612. Epub 2018 Apr 29.
3
Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma.
检查转移性肾细胞癌中使用的靶向治疗相关出血事件。
Crit Rev Oncol Hematol. 2017 Dec;120:151-162. doi: 10.1016/j.critrevonc.2017.10.014. Epub 2017 Nov 1.
4
Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database.日本药品不良事件报告数据库中主动脉夹层与血管内皮生长因子通路抑制剂全身暴露之间的关联
Circulation. 2017 Feb 21;135(8):815-817. doi: 10.1161/CIRCULATIONAHA.116.025144.
5
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.靶向血管内皮生长因子受体的癌症治疗对中心血压和心血管系统的影响
Am J Hypertens. 2016 Feb;29(2):158-62. doi: 10.1093/ajh/hpv077. Epub 2015 Jun 1.
6
Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years.一名接受多种酪氨酸激酶抑制剂治疗5年的患者发生急性主动脉夹层。
Aktuelle Urol. 2014 Mar;45(2):132-4. doi: 10.1055/s-0033-1363274. Epub 2014 Apr 3.